Spero Therapeutics is a clinical-stage biopharmaceutical company advancing innovative medicines for immune-mediated and infectious diseases. Its pipeline includes SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease, alongside earlier programs in antibacterial and rare-disease therapeutics. - View it on GitHub